Imagine you have a tumor, a dangerous cell cluster waging war within your body. Now, imagine scientists using a special kind of scan called Positron Emission Tomography (PET) to watch how your immune system responds to this invader. This isn’t just about the tumor anymore; it's about understanding h
Ever felt like your voice doesn't matter in politics? It's not just you. The U. S. is seeing a dramatic increase in money influencing elections, thanks to a 2010 Supreme Court decision. This decision allowed rich people and businesses to spend unlimited amounts on campaigns, a move that's changed th
West Ham United's boss, Julen Lopetegui, is still in charge despite two big losses in the Premier League. He's been at the club's training ground as usual, even though talks are happening with Graham Potter about taking over. Lopetegui's job is on the line because West Ham hasn't won two games in a
Ever wondered what could have been? Microsoft designer Sergey Kisselev, who worked on the Windows team, recently shared some fascinating "dynamic wallpaper" designs for Windows 11 that never saw the light of day. These concepts, found on Behance, showcase a range of vibrant and moving backgrounds th
Imagine you're battling advanced biliary tract cancer (ABTC), and your doctors suggest a mix of drugs: nivolumab, modified gemcitabine, and S-1. This combo showed promise in a past trial, but PD-L1 levels didn't tell us much about how well it would work. So, scientists looked at another marker, LAG-
You might not think about it, but the time of day you get your cancer treatment could make a difference. Scientists have been looking into how our body's internal clock, called the circadian rhythm, affects how well cancer drugs work. One type of drug, called immune checkpoint inhibitors (ICIs), has
Immune treatments, or immune checkpoint inhibitors (ICIs), are game-changers for some people with far-advanced solid tumors. But when it comes to biliary tract cancer (BTC), doctors are still figuring out who gets the most benefit from these treatments. A recent trial focused on pembrolizumab, an IC
Biliary tract cancers, like cholangiocarcinoma and gallbladder cancer, are growing more common worldwide, and most patients get diagnosed when the disease has already advanced, leading to a grim outlook. Recently, combining immune checkpoint inhibitors, such as durvalumab and pembrolizumab, with the
China Dongxiang (Group) Co (HK:3818) has some news for its shareholders. The company is planning to take back unclaimed dividends that date back to 2013. If you're a shareholder, you have until January 14, 2025, to claim what’s yours. In other developments, the company has added a new face to its le
Intermittent fasting, often touted as a weight loss and health improvement strategy, faces uncertainty when it comes to its effects on liver function, especially in adults dealing with metabolic disorders. To dig deeper, researchers conducted a systematic review and meta-analysis. They wanted to und
